Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy

Eye (Lond). 2018 Jan;32(1):55-66. doi: 10.1038/eye.2017.290. Epub 2017 Dec 21.

Abstract

PurposeTo correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (ie oral eplerenone, half-fluence photodynamic therapy (PDT)).Patients and methodsTwenty eyes of 16 consecutive patients with treatment-naïve CSC undergoing either eplerenone or PDT were enrolled in this prospective, observational study. All patients underwent structural OCT and OCT-A at baseline and after therapy at months 1 and 3.ResultsEleven eyes of nine patients and nine eyes of seven patients underwent eplerenone or PDT treatment, respectively. Central macular thickness (CMT) and subretinal fluid (SRF) correlated to fovea avascular zone (FAZ) area (r=0.74 and r=0.71, P=0.01) and vessel density (r=0.77 and r=0.68, P=0.01) at deep capillary plexus (DCP). CMT (P=0.0011), SRF (P=0.0005), SFCT (P=0.0016), FAZ area at DCP (P=0.0334) improved at 3-month visit. A significant reduction of deep FAZ area was appreciated in eplerenone (P=0.0204) but not in PDT (P=0.5) group. SFCT reduction was significantly higher in PDT than eplerenone group (P=0.0347).ConclusionStructural and vascular parameters are correlated in CSC and they improve after different treatments. Both half-fluence PDT and oral eplerenone do not permanently damage choriocapillaris or other choroidal layers as evaluated by OCT-A.

MeSH terms

  • Administration, Oral
  • Adult
  • Central Serous Chorioretinopathy / diagnosis
  • Central Serous Chorioretinopathy / drug therapy*
  • Choroid / pathology
  • Eplerenone
  • Female
  • Fluorescein Angiography / methods*
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / administration & dosage
  • Multimodal Imaging*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use*
  • Prospective Studies
  • Retina / pathology
  • Spironolactone / administration & dosage
  • Spironolactone / analogs & derivatives*
  • Tomography, Optical Coherence / methods*
  • Visual Acuity

Substances

  • Mineralocorticoid Receptor Antagonists
  • Photosensitizing Agents
  • Spironolactone
  • Eplerenone